5-NIdR

• CAT Number: M045097
• CAS Number: 191421-10-0
• Molecular Formula: C13H14N2O5
• Molecular Weight: 278.26
• Purity: ≥95%
• Synonyms: (2R,5R)-2-(hydroxymethyl)-5-(5-nitroindol-1-yl)oxolan-3-ol
• InChI: InChI=1S/C13H14N2O5/c16-7-12-11(17)6-13(20-12)14-4-3-8-5-9(15(18)19)1-2-10(8)14/h1-5,11-13,16-17H,6-7H2/t11?,12-,13-/m1/s1
• InChIKey: ODPRBLIUAVWXNM-VFRRUGBOSA-N
• SMILES: C1C(C(OC1N2C=CC3=C2C=CC(=C3)[N+](=O)[O-])CO)O

5-NIdR (1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole), an artificial nucleoside, exhibits the ability to inhibit the replication of DNA lesions generated by Temozolomide (HY-17364). 5-NIdR induces cancer cells apoptosis and arrests cell cycle at G0 phase. 5-NIdR enhances Temozolomide anti-tumor efficacy in murine glioblastoma model[1].
5-NIdR (12.5-100 μM; 24-72 h) inhibits the growth of human glioblastoma cell lines (U87, A172, and SW1088) in a dose-dependent manner[1].
5-NIdR (1-100 μg/mL; 72 h) induces cell apoptosis in U87 cells, and arrests cell cycle at G0 phase with 100 μg/mL overnight incubation[1].
5-NIdR (100 mg/kg; ip; for 5 consecutive days), together with Temozolomide (40 mg/kg), results complete tumor regression in a murine xenograft model of glioblastoma. Temozolomide alone only delayed tumor growth[1].

Reference

[1]. Choi JS, et al. Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer. Cancer Res. 2018 Feb 15;78(4):1083-1096.
 [Content Brief]